Cargando…

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms

Antibodies with the same variable region can exist as multiple isotypes with varying neutralization potencies, though the mechanism for this is not fully defined. We previously isolated an HIV-directed IgA1 monoclonal antibody (mAb), CAP88-CH06, and showed that IgA1 and IgG3 isotypes of this antibod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moyo-Gwete, Thandeka, Scheepers, Cathrine, Makhado, Zanele, Kgagudi, Prudence, Mzindle, Nonkululeko B., Ziki, Rutendo, Madzorera, Sharon, Manamela, Nelia P., Ayres, Frances, Lambson, Bronwen E., Richardson, Simone I., Morris, Lynn, Moore, Penny L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526727/ https://www.ncbi.nlm.nih.gov/pubmed/36182959 http://dx.doi.org/10.1038/s41598-022-20141-7

Ejemplares similares

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
por: Scheepers, Cathrine, et al.
Publicado: (2020)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022)

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2023)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
por: Mandolo, Jonathan, et al.
Publicado: (2021)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2021)

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies
por: Mabvakure, B., et al.
Publicado: (2017)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection
por: Moore, Penny L., et al.
Publicado: (2009)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
por: Krause, Robert G. E., et al.
Publicado: (2023)

Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent
por: Noailly, Blandine, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
por: Chibwana, Marah G., et al.
Publicado: (2022)

Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses
por: Lubow, Jay, et al.
Publicado: (2023)

Equal Neutralization Potency of Antibodies Raised against Abrin Subunits
por: Gal, Yoav, et al.
Publicado: (2020)

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
por: Noval, Maria G., et al.
Publicado: (2021)

Characterization of an Isotype-Dependent Monoclonal Antibody against Linear Neutralizing Epitope Effective for Prophylaxis of Enterovirus 71 Infection
por: Lim, Xiao Fang, et al.
Publicado: (2012)

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
por: Ryu, Dong-Kyun, et al.
Publicado: (2021)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Development of an in Vitro Potency Assay for Anti-anthrax Lethal Toxin Neutralizing Antibodies
por: Whiting, Gail, et al.
Publicado: (2012)

Symmetrical Modification of Minimized Dermaseptins to Extend the Spectrum of Antimicrobials with Endotoxin Neutralization Potency
por: Shao, Changxuan, et al.
Publicado: (2019)

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
por: Rujas, Edurne, et al.
Publicado: (2022)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
por: Cele, Sandile, et al.
Publicado: (2021)

Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan
por: Umotoy, Jeffrey, et al.
Publicado: (2019)

Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
por: Lim, Shion A., et al.
Publicado: (2021)

Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
por: Mabvakure, Batsirai M., et al.
Publicado: (2019)

A single, continuous metric to define tiered serum neutralization potency against HIV
por: Hraber, Peter, et al.
Publicado: (2018)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
por: Richardson, Simone I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9bsql34af9ofsgiio01ug8f9ip